Research Article
The Impact of COVID-19 Vaccines on Male Semen Parameters: A Retrospective Cohort Study
Table 1
Descriptive statistics of the cohort (
).
| | Variables | Mean ± SD |
| | Age (years) | 38.0 ± 5.5 | | Days between vaccination and pre-semen analysis | 45.2 ± 27.7 | | Days between vaccination and post-semen analysis | 110.3 ± 50.1 | | Days between pre and post-semen analysis | 155.4 ± 53.9 |
| | Vaccine received | (%) |
| | Pfizer-BioNTech (BNT162b1) | 29 (63.0%) | | Johnson and Johnson (JNJ-78436735/Ad26.COV2S) | 16 (34.8%) | | AstraZeneca (AZD1222) | 1 (2.2%) |
| | Semen analysis abnormalities | (%) |
| | Patients with normozoospermia† (prevaccination) | 15 (32,6%) | | Patients with normozoospermia† (postvaccination) | 14 (30.4%) | | Patients with oligozoospermia‡ (prevaccination) | 14 (30.4%) | | Patients with oligozoospermia‡ (postvaccination) | 10 (21.7%) | | Patients with progressive motility <32% (prevaccination) | 9 (19.5%) | | Patients with progressive motility <32% (postvaccination) | 12 (26.1%) | | Patients with teratozoospermia§ (prevaccination) () | 14 (36.8%) | | Patients with teratozoospermia§ (postvaccination) () | 14 (36.8%) |
|
|
†Normozoospermia = Sperm concentration ≥ 15 x 10 6/mL, Progressive motility ≥ 32 %, and normal morphology ≥ 4 %; ‡Oligozoospermia = Sperm concentration < 15 x 10 6/ mL; §Teratozoospermia = Normal sperm morphology < 4 %.
|
